Frankfurt
14.10.25 | 08:15
0,328 Euro
-2,38 % -0,008
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,340 | 0,352 | 19:43 | |
| 0,340 | 0,352 | 19:25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:02 | IGC Pharma, Inc.: IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences | 96 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative... ► Artikel lesen | |
| Sa | IGC Pharma, Inc.: IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders | 478 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop... ► Artikel lesen | |
| Sa | IGC Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.10. | IGC Pharma, Inc.: IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease | 153 | ACCESS Newswire | IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IGC... ► Artikel lesen | |
| 01.10. | IGC Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| IGC PHARMA Aktie jetzt für 0€ handeln | |||||
| 29.09. | IGC Pharma, Inc.: IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial | 208 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an... ► Artikel lesen | |
| 24.09. | IGC Pharma, Inc.: IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology | 137 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's... ► Artikel lesen | |
| 22.09. | IGC Pharma, Inc.: IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial | 172 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has... ► Artikel lesen | |
| 09.09. | IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection | 119 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its... ► Artikel lesen | |
| 02.09. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada | 204 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment... ► Artikel lesen | |
| 28.08. | IGC Pharma, Inc.: IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome | 215 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO)... ► Artikel lesen | |
| 27.08. | IGC Pharma, Inc.: IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." | 239 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / August 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We... ► Artikel lesen | |
| 25.08. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City | 241 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug... ► Artikel lesen | |
| 19.08. | IGC Pharma GAAP EPS of -$0.02 beats by $0.01, revenue of $0.33M misses by $0.16M | 2 | Seeking Alpha | ||
| 19.08. | IGC Pharma, Inc.: IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial | 477 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments... ► Artikel lesen | |
| 12.08. | IGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 | 928 | ACCESS Newswire | Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the worldAlzheimer's affects over 50 million people globally, with more than... ► Artikel lesen | |
| 05.08. | IGC Pharma, Inc.: IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression | 213 | ACCESS Newswire | - New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"... ► Artikel lesen | |
| 23.07. | IGC Pharma, Inc.: IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 | 212 | ACCESS Newswire | - Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma... ► Artikel lesen | |
| 21.07. | IGC Pharma, Inc.: IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards | 305 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist... ► Artikel lesen | |
| 10.07. | IGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection | 417 | ACCESS Newswire | - Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 27,330 | -1,53 % | Bayer-Aktie: Erneut gescheitert - darum fällt der DAX-Wert deutlich | Rote Laterne für die Aktie von Bayer im DAX. Am Dienstag verliert der Titel zeitweise gut vier Prozent an Wert und distanziert sich damit wieder von der charttechnischen Widerstandszone um die Marke... ► Artikel lesen | |
| NOVO NORDISK | 48,745 | -2,21 % | BioNTech Aktie: Spannung! - IBU-tec, Novo Nordisk, Rheinmetall, Valneva und Verbio im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| PFIZER | 21,290 | -0,37 % | Wo noch Wachstum stattfindet - PanGenomic Health, Redcare Pharmacy, Pfizer | Die deutsche Industrie meldete zum wiederholten Male weniger Aufträge. Zum vierten Mal in Folge setzte sich der Negativtrend fort und im August fielen die Neuaufträge um 0,8 % unterhalb des Vormonats... ► Artikel lesen | |
| NOVARTIS | 112,16 | +0,88 % | EQS-News: Novartis Pharma GmbH: Novartis ernennt Manfred Heinzer zum neuen Vorsitzenden der Geschäftsführung in Deutschland | EQS-News: Novartis Pharma GmbH
/ Schlagwort(e): Personalie
Novartis ernennt Manfred Heinzer zum neuen Vorsitzenden der Geschäftsführung in Deutschland
07.10.2025 / 15:00... ► Artikel lesen | |
| MERCK KGAA | 115,35 | -2,04 % | EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Merck KGaA
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| GILEAD SCIENCES | 102,34 | +0,12 % | Gilead Sciences, Inc.: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 | Late-breaking Phase 3 ASCENT-03 Study Results Highlight Potential for Trodelvy to Redefine First-Line Metastatic Triple-Negative Breast Cancer Treatment New EDGE-Gastric Overall Survival Results... ► Artikel lesen | |
| AURORA CANNABIS | 4,675 | -0,64 % | Piramal Pharma Solutions Implements POD Method at Aurora API Facility | ||
| SANOFI | 84,24 | +0,26 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 110 Euro belassen. Die kürzlich vorgestellten Studiendaten zu Amlitelimab bei Asthma... ► Artikel lesen | |
| ABBVIE | 197,20 | -1,00 % | Abbvie - ABBV: Berenberg-Bank JETZT mit "KAUFEN"! | Kursziel 270 USD! Skyrizi & Rinvoq lösen Humira als Umsatzbringer für Abbvie ab! Marktführer bei Immunologie! Abbvie (ABBV) - ISIN US00287Y1091 Rückblick: Mit einem Kursplus von rund 30 Prozent beeindruckte... ► Artikel lesen | |
| CANOPY GROWTH | 1,174 | -1,18 % | Canopy Growth Corp - 8-K, Current Report | ||
| ELI LILLY | 703,80 | -0,61 % | Eli Lilly: Die Bullen scheinen zurück - Trendwende geglückt? | Trendbetrachtung auf Basis 6 Monate: Die letzten Monate hatten es in sich. Nach einem beachtlichen Höhenflug zu Jahresbeginn kam es bei der Aktie des US-amerikanischen Pharmaunternehmens zu einer deutlichen... ► Artikel lesen | |
| MERCK & CO | 73,30 | -0,95 % | Merck Sharp & Dohme: Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025 | Positive survival data from KEYNOTE-905 and KEYNOTE-B96 to be featured in Presidential Symposium, underscoring the impact of KEYTRUDA (pembrolizumab) in certain bladder and ovarian cancers Data... ► Artikel lesen | |
| ASTRAZENECA | 146,05 | -0,27 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Astrazeneca auf "Outperform" mit einem Kursziel von 18000 Pence belassen. Der Pharmakonzern habe positive und... ► Artikel lesen | |
| HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| TILRAY BRANDS | 1,401 | -4,99 % | Tilray-Aktie explodiert nach Quartalszahlen - echter Turnaround oder Strohfeuer? |
IGC PHARMA INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,328 Euro und damit -2,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IGC PHARMA INC finden Sie auf Wallstreet Online.